Get the Stockscreener App
2.065
2.84%
-0.045
Lipocine Inc stock is traded at $2.065, with a volume of 23,895.
It is down -2.84% in the last 24 hours and down -8.07% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$2.11
Open:
$2.09
24h Volume:
23,895
Relative Volume:
0.35
Market Cap:
$16.91M
Revenue:
$2.00M
Net Income/Loss:
$-11.43M
P/E Ratio:
-1.0552
EPS:
-1.957
Net Cash Flow:
$-10.05M
1W Performance:
-2.38%
1M Performance:
-8.07%
6M Performance:
-78.31%
1Y Performance:
-32.28%
1-Day Range:
$2.05
$2.13
1-Week Range:
$2.02
$2.2237
52-Week Range:
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.0506 | 17.40M | 2.00M | -11.43M | -10.05M | -1.957 |
VRTX
Vertex Pharmaceuticals Inc
|
515.52 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.63 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.26 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.10 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake - Stock Titan
Weekly Recap: Q2 revenue drop and Brilzio partner search - TradingView
Lipocine Inc. (NASDAQ: LPCN) awards director 2,000 stock options - Stock Titan
Lipocine Inc. (LPCN) director Grissinger files initial ownership statement - Stock Titan
Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Lipocine files Form 3 initial beneficial ownership statement for director Michael Grissinger - Bitget
Lipocine Inc (LPCN) Stock News Today - TradingKey
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Lipocine (LPCN) and High Tide (HITI) - The Globe and Mail
Lipocine (LPCN) Slips 1.8% to $2.13 as Biotech Stock Holds Above Key $2.02 SupportMcClellan Oscillator - dars.gov.et
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lipocine Inc (LPCN) Earnings Date & Reports & Earnings News - TradingKey
Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock News, LPCN Share Price & Updates - Kalkine
Lipocine Q2 net loss widens as revenue declines - TradingView
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 - PR Newswire
Lipocine posts $2.6 million Q2 net loss as revenue falls - Quiver Quantitative
Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q Summary - TradingView
Lipocine (NASDAQ: LPCN) widens H1 loss but extends cash runway to 2027 - Stock Titan
Lipocine Appoints Michael J. Grissinger to Board of Directors - Morningstar
Lipocine Appoints Industry Veteran Grissinger to Board - TipRanks
Lipocine appoints Michael Grissinger to board of directors By Investing.com - Investing.com Australia
Lipocine appoints Michael Grissinger to board of directors - Investing.com India
Lipocine Inc. Announces Appointment of Michael J. Grissinger to Board of Directors, Effective August 3, 2026 - marketscreener.com
Lipocine Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Lipocine Inc (LPCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lipocine Inc (LPCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LPCN|Lipocine Inc|Price:2.160|Chg%:+0.080 - TradingKey
Lipocine Inc (LPCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lipocine Inc (LPCN) Income Statement - TradingKey
Lipocine Inc (LPCN) Balance Sheet - TradingKey
Lipocine Inc (LPCN) Cash Flow - TradingKey
Lipocine Inc. (LPCN) Q1 2026 Earnings: EPS Miss Pressures Shares as Pipeline Progress Remains KeyNet Profit Margin - dars.gov.et
LPCN|Lipocine Inc|Price:2.080|Chg%:-0.110 - TradingKey
Lipocine Inc (LPCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lipocine Inc (LPCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lipocine Market Sentiment - Benzinga España
LPCN|Lipocine Inc|Price:2.210|Chg%:-0.020 - TradingKey
Lipocine (LPCN) Faces Slight Pullback Amid Sector VolatilityRSI Overbought Alerts - dars.gov.et
Lipocine Inc. (LPCN) Holds Near Support After Modest Gain, Resistance in FocusBull Pennant - dars.gov.et
Lipocine Inc. (LPCN) Approaches Key Support After 2.85% Decline – Technical Levels in FocusFibonacci Arc - dars.gov.et
LPCN Q1 2026 Earnings: Wider-Than-Expected Loss Drags Shares LowerHealthcare Earnings Report - dars.gov.et
Form 4 Lipocine Inc For: 30 June By Investing.com - Investing.com Canada
Lipocine (LPCN) CEO Mahesh Patel receives 52,781 stock options grant - Stock Titan
LPCN Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline Progress Remains KeyProfit Inflection Point - dars.gov.et
Lipocine Inc. (LPCN) Narrows Slightly, Holds Within Key RangeVolatility Breakout Picks - dars.gov.et
Enterprise value to revenue forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Price to book forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Price to earnings forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Enterprise value to EBITDA forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Price to sales forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Enterprise value to EBIT forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Lipocine Inc Actuals & Estimates (NASDAQ:LPCN) - TradingView
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lipocine Inc Stock (LPCN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Higuchi John W. | Director |
Apr 06 '26 |
Buy |
2.05 |
123,000 |
252,150 |
163,797 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 06 '26 |
Buy |
2.03 |
25,000 |
50,750 |
160,679 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 02 '26 |
Buy |
2.02 |
25,000 |
50,500 |
135,679 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):